Navigation Links
Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
Date:11/24/2009

NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Piper Jaffray 21st Annual Health Care Conference being held in New York City.

Mr. Bentsur's presentation will be webcast live on Wednesday, December 2nd at 10:30AM ET and will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 is currently in Phase 2 clinical development for multiple tumor types, with a Phase 3 in multiple myeloma, under Special Protocol Assessment (SPA), pending commencement by year-end. Keryx is also developing Zerenex(TM) (ferric citrate), an oral, iron-based compound that has the capacity to bind to phosph
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
11. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... ALISO VIEJO, Calif. , May 22, 2013  Avanir ... company management will present an overview of the company at ... Health Care Conference , Presentation date: Wednesday May 29, ... , Jefferies 2013 Global Healthcare Conference , Presentation ... a.m. E.T. A live ...
(Date:5/22/2013)... , May 22, 2013  Flagship Ventures, ... focused on healthcare and sustainability, today announced the ... as a Senior Partner. In this role, Mr. ... portfolio companies. In addition to working ... Bancel also serves as President and Chief Executive ...
(Date:5/22/2013)... , May 22, 2013  Grifols, a global healthcare ... presented results from a study demonstrating that a higher ... [Human]) increased levels of the alpha 1 protein ... levels that are considered within the normal range for ... in which low levels of the alpha 1 ...
Breaking Medicine Technology:Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 2Life Science Industry Veteran Stephane Bancel Joins Flagship Ventures 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 2Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 3Grifols study demonstrates higher dose of PROLASTIN-C increases levels of alpha1-PI to within normal range in patients with AAT deficiency 4
(Date:5/22/2013)... Yoga of Lady Niguma was created by a female yogi (‘yogini’) ... the oldest yoga found in written form (in a book made ... renowned Indian master and yogi Naropa, and the yoga she created ... master. , Lady Niguma taught the practice to her student ... lineage to the second Dalai Lama, Gendun Gyatso. While researching rare ...
(Date:5/22/2013)... A new study published online today (Thursday) in the ... who visited fast food or chain restaurants in the U.S. ... likely to use calorie information given in the restaurants to ... eating at fast food or chain restaurants twice a week ... as those eating there once a week or less. , ...
(Date:5/22/2013)... Hosted by the California Dental Association Foundation and ... than $1.6 million in charitable dental services during the ... , The California Dental Association Foundation and the California ... services and oral health education to Californians who experience ... by CDA and CDAF in the past 12 months. ...
(Date:5/22/2013)... Zensah® Compression Apparel released a statement ... titled "Breast pain while running affects one-third of ... help." According to the article, a British study surveyed ... suffer from breast pain while running but do not ... , Zensah emphasizes the importance for women to ...
(Date:5/22/2013)... Reporter , , WEDNESDAY, May 22 (HealthDay News) -- People ... likely to attempt suicide, whether or not they also ... a new study. "Clinicians who are seeing patients ... at increased risk of suicide," said study co-author Mark ... Resource and Evaluation Center in Ann Arbor, Mich. ...
Breaking Medicine News(10 mins):Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 2Health News:Popular Yoga DVD, Lady Niguma Yoga Released for Sale Online 3Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 2Health News:STRICTLY EMBARGOED UNTIL 6:00AM EST THURSDAY May 23, 2013; Calorie Information in Fast Food Restaurants Used by 40% of 9-18 Year Olds when Making Food Choices, Study Finds 3Health News:Two-day San Jose Dental Clinic Provides More Than $1.6 Million in Care 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 2Health News:Zensah® Comments on New York Daily News Article Examining How Better Sports Bra Could Help Women Marathoners 3Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 2Health News:Migraine, Chronic Back Pain Tied to Higher Suicide Risk 3
... new study from Harvard School of Public Health (HSPH) and ... between the common sexually transmitted infection, Trichomonas vaginalis ... in men. The study appears online on September 9, ... website and will appear in a later print edition. ...
... H1N1 influenza vaccine in pregnant women is launching this ... (NIAID), part of the National Institutes of Health, announced ... severe illness if they become infected with influenza virus ... to receive the seasonal influenza vaccine every year," says ...
... , , CAMARILLO, Calif., Sept. ... National Science Foundation (NSF) recently honored Dr. Blake Gillespie, Assistant ... Development (CAREER) award. , , The ... and research in protein-ligand interactions and biomolecular dynamics, is supported ...
... extend to staph infections, researchers say , WEDNESDAY, Sept. ... anti-microbial properties, might kill MRSA bacteria. , A new ... the honey, made solely from flowers found on the ... FabI protein, which is needed for fatty acid biosynthesis. ...
... to awaken dormant, common virus that crosses over into brain ... discovered part of the reason why Tysabri, a drug used ... a rare but potentially deadly brain disease in some patients. ... virus from its slumber, allowing it to cross into the ...
... , WASHINGTON, Sept. 9 Statement of ... Legal Reform, on reports from White House press secretary Robert ... tonight,s speech to Congress: , , (Logo: ... "We are encouraged that President Obama understands the tremendous ...
Cached Medicine News:Health News:Link found between common sexual infection and risk of aggressive prostate cancer 2Health News:NIAID launches 2009 H1N1 influenza vaccine trial in pregnant women 2Health News:CI Faculty Member Awarded Nearly $1 Million NSF Grant 2Health News:MRSA May Succumb to Honey 2Health News:Scientists Find Clue to Dangerous Side Effect of MS Drug 2Health News:Scientists Find Clue to Dangerous Side Effect of MS Drug 3Health News:U.S. Chamber Encourages Obama to Propose Meaningful Medical Liability Reforms in Speech to Congress 2